His genetic workup showed a homozygous variant in exon 9 of the low-density lipoprotein receptor (LDLR) gene of chromosome 19 and was classified as having homozygous familial hypercholesterolemia. His treatment was intensified to the maximum tolerated dosage of statin and ezetimibe but LDL was far above the acceptable limit, so he was planned for monthly injections of proprotein convertase subtilisin/kexin type 9 protein (PCSK9) inhibitor, evolocumab. The gene discussed is VLDLR; the disease is familial hypercholesterolemia.